~ Buy the ZAVZPRET (zavegepant hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

zavzpret Drug Patent Profile

✉ Email this page to a colleague

When do Zavzpret patents expire, and what generic alternatives are available?

Zavzpret is a drug marketed by Pfizer and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-one patent family members in thirty-five countries.

The generic ingredient in ZAVZPRET is zavegepant hydrochloride. Two suppliers are listed for this compound. Additional details are available on the zavegepant hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zavzpret

Zavzpret will be eligible for patent challenges on March 9, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 9, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for zavzpret?
What are the global sales for zavzpret?
What is Average Wholesale Price for zavzpret?

Summary for zavzpret

International Patents:	71
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	21
Drug Prices:	Drug price information for zavzpret
What excipients (inactive ingredients) are in zavzpret?	zavzpret excipients list
DailyMed Link:	zavzpret at DailyMed

Drug patent expirations by year for zavzpret

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for zavzpret

Generic Entry Date for zavzpret^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 216386 Dosage: SPRAY, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for zavzpret

Drug Class	Calcitonin Gene-related Peptide Receptor Antagonist
Mechanism of Action	Calcitonin Gene-related Peptide Receptor Antagonists

US Patents and Regulatory Information for zavzpret

zavzpret is protected by two US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of zavzpret is ⤷ Sign Up.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting zavzpret

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

FDA Regulatory Exclusivity protecting zavzpret

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for zavzpret

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023	⤷ Sign Up	⤷ Sign Up
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for zavzpret

See the table below for patents covering zavzpret around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Israel	221665	R-n-) 3-3-) 7-מתיל-1h-אינדאזול-5-איל)-1-(4-(1-מתילפיפרידינ-4-איל)פיפראזיינ-l -איל) 1-אוקסופרופאנ-2-איל)-4-(2-אוקסו-1,2-דיהידרוקווינולינ-3-איל)פיפרידינ-1-קרבוקסאמיד, הרכבים רוקחי ים המכילים אותו ןשימושם (R-n-(3-3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-l-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidin-1-carboxamide, pharmaceutical compositions comprising it and use thereof)	⤷ Sign Up
Taiwan	I483937		⤷ Sign Up
Singapore	183918	CGRP RECEPTOR ANTAGONIST	⤷ Sign Up
Mexico	2012010725	ANTAGONISTA DEL RECEPTOR DE PEPTIDO RELACIONADO CON EL GEN DE LA CALCITONINA (CGRP). (CGRP RECEPTOR ANTAGONIST.)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2011123232		⤷ Sign Up
Serbia	104004	ANTAGONISTI, PEPTIDNOG RECEPTORA KOJI JE U VEZI SA KALCITONINSKIM GENOM (CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS)	⤷ Sign Up
European Patent Office	1539766	ANTAGONISTES DES RECEPTEURS DU PEPTIDE RELIE AU GENE DE LA CALCITONINE (CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration